SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Trends > Omega-3

Fluxome finds a last-minute buyer: But is it resveratrol or omega-3 to be sold?

By Shane Starling+

22-Nov-2012

A deal has been struck for part of Fluxome's business: But which part?
A deal has been struck for part of Fluxome's business: But which part?

Swiss biotech firm Evolva has agreed to buy undisclosed assets from Fluxome, as it leaves its pure pharma research past in the dust and throws the embattled Danish supplier a lifeline.

Evolva chief financial officer Jakob Dynnes Hansen told NutraIngredients the deal would conclude, “in a couple of weeks” regulatory approval forthcoming, at which time it would become apparent which part of Fluxome’s business had been acquired – resveratrol or its advanced yeast derived omega-3 research programme.

Fluxome, which shut shop on the Danish branch of its operation at the end of September as its resveratrol business faltered, has been in a “formal reconstruction”  (a form of bankruptcy under Danish law) process that will consider the Evolva offer and other aspects in Danish courts on November 28.

 Chairman Jarne Elleholm said his firm was delighted by Evolva’s bid, and that negotiations with other parties were ongoing for the remaining part of the business.

“We are waiting for approval  but Evolva is a good company that can take this forward as they are dedicated to the area and have a scientific pedigree. Fluxome will be split in two.”

It is unknown what affect this will have on the US operation, which has continued running amid the crisis.

Elleholm said the 21 former employees at the Danish operation have been informed of the developments.

Evolva: Pharma to food

Dynnes Hansen said the move was a good one for a firm now fully committed to the nutra space, after years of pharma biotech research.

 “We were founded with a pharma focus as are most biotech companies – until 2-3 years ago when we started with stevia so now we have shifted completely away from pharma and are focusing on food and nutrition,” Dynnes Hansen said. “Now we are almost exclusively non-pharma other than a little outsourced research for the likes of Roche.”

Evolva gained a stevia line after it bought US firm Abunda Nutrition in 2010.

“We had companies that wanted to use our technology outside the pharma area and we found out our technology was suitable and there was good demand for it in nutrition. So we have moved that way. There is not the same risk profile as pharma especially the later stages of development. It is high cost and high risk.”

The global resveratrol supply market is valued at about €40m according to Frost and Sullivan data, with 90% of volumes accounted for by the US food supplements market.

Frost said Europe would retain second place in the market with the Asia Pacific region growing the fastest – especially Australia and New Zealand. Frost differentiated between the food supplements and functional food markets.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars